Asian Research Journal of Gynaecology and Obstetrics

Ovarian reserve indicates the quantity and quality of Ovarian primordial follicles. Poor ovarian reserve (POR) indicates the reduction in the quantity of ovarian follicular pool in women of reproductive age group. In recent years, autologous stem cell therapy has emerged as a promising avenue in the realm of reproductive medicine, offering new hope to patients with POR

Aims: To evaluate the ovarian response (FSH, LH, AMH and Antral follicular Count) after autologous stem cell therapy

To assess the pregnancy rate after autologous stem cell therapy

Study Design: Prospective Observational study

Place and Duration of Study: The study was conducted in a fertility clinic from June 2022 to June 2023.

Methodology: This prospective observational study was conducted in a Fertility clinic(Srikarii Hospital, Hospet, Karnataka) for one year, from June 2022 to June 2023. The study was done among women diagnosed with poor ovarian reserve with infertility. Autologous bone marrow-derived stem cell therapy was given as a part of fertility treatment. Hormonal assays and Antral Follicular Counts were measured before and after the stem cell therapy. The improvement in ovarian function was assessed. Pregnancy rates were also assessed.

Results: The present study was conducted among 8 women, The mean age of the study participants was 32.1± 6.33 years (minimum age 20 years and max age 39 years). The serum Anti Mullerian Hormone levels and Antral follicular counts showed a significant change after the stem cell therapy. The mean baseline AMH was 0.371 ±0.198 ng/l, and at the end of 3rd month, AMH was 0.786 ±0.353 ng/l. Pregnancy rates after the procedure were about 71%

Conclusion: Autologous bone marrow-derived stem cell therapy has emerged as a new hope for ovarian rejuvenation for women with poor ovarian reserve. Clinical application of this in the reproductive medicine practice helps to solve the challenge of infertility associated with poor ovarian reserve.